MaRS Innovation to act as commercialization agent for York's life sciences and technology discoveries, leveraging new potential for York's existing $70 million in research initiatives
TORONTO, May 9, 2011 – York University has become the latest member of MaRS Innovation, the commercialization agent for many leading Toronto-based universities, hospitals and research institutes.
“York has become one of Canada’s fastest-growing centres for research and innovation,” said Stan Shapson, vice-president Research & Innovation at York University. “We typically get 10 to 20 discovery disclosures a ...
Matt Galloway, host of CBC's Metro Morning, spoke to Prateek Dwivedi, vice-president and chief information officer at Mount Sinai Hospital, about VitalHub's technology.
Dwivedi's interview with Galloway is no longer publicly available.
Dwivedi and Galloway touch on various product highlights, including:
Longitudinal view of a patient's history and benefits of having access to that information when making rounds or walking between locations.
Security concerns, including encryption, that are equivalent to those used in the hospital.
Feedback from doctors, nurses and others who have used the product.
TORONTO, ON (Jan. 25, 2011) —Doctors, nurses and administrators can now access electronic health applications on mobile, hand-held technology through VitalHub Corp..
The unique start-up company was spun-off from mobile health technologies developed Toronto's Mount Sinai Hospital, thanks in part to $300,000 in seed financing from MaRS Innovation that will give it a crucial head start in the fiercely competitive mobile IT health sector.
MaRS Innovation invests in the most commercially promising discoveries emerging from its member institutions, which include 16 of Toronto's ...
Funds secured from MaRS Innovation, HTX, OICR and CCR to speed commercialization of Xagenic's rapid molecular diagnostic technology
TORONTO (October 13, 2010) – MaRS Innovation today announced a $500,000 investment in its Toronto-based spin-off company, Xagenic Inc.
When combined with funds from other investors and lenders, the new working capital provided to Xagenic totals $1.04 million.
This follow‐on financing includes a $300,000 loan from HTX, The Health Technology Exchange; $200,000 from the Ontario Institute for Cancer Research; $40,000 from the Ontario Centre of Excellence ...